InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.00%
)
US TECH 100
19,190.80
(
0.08%
)
Dow Jones
39,112.16
(
0.00%
)
Brent Oil
84.69
(
0.59%
)
Bitcoin
61,357.19
(
-0.73%
)
Post# of 252360
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: mcbio post# 210484

Thursday, 04/06/2017 10:37:15 AM

Thursday, April 06, 2017 10:37:15 AM

Post# of 252360
ACRS:

I would appreciate a clarification on this one. As I said, my patents knowledge stinks.

- They're receiving patents on the use of someone else's compounds in a specific indication?

- If they have a novel compound with its own IP, why do they need use patents of baricitinib / juxolitinib? Is it in an attempt to block the latter two from being used in that indication?

- Incyte is moving ahead with a topical formulation in this indication. Is that due to these patent applications?

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up